Please assess the completion status of the following clinical trial:

Trial Title: Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Successful completion of Protocol PB-06-001~* The patient signs informed consent~Exclusion Criteria:~* Currently taking another experimental drug for any condition~* Presence of severe neurological signs and symptoms, defined as complete ocular paralysis, overt myoclonus or history of seizures, characteristic of neuronopathic Gaucher disease~* Pregnant or nursing~* Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient's compliance with the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Naive 30 Units/kg (Type: EXPERIMENTAL): Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
- Naive 60 Units/kg (Type: EXPERIMENTAL): Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
- Switchover (Type: EXPERIMENTAL): Continue taliglucerase alfa treatment from PB-06-002 (NCT00712348)

Based on this trial design, predict the completion outcome and termination type (if applicable).